Hemoglobin A1C


Introduction

The hemoglobin A1c (glycated hemoglobin, glycosylated hemoglobin, HbA1c, or A1c) test is used to evaluate a person's level of glucose control. The test shows an average of the blood sugar level over the past 90 days and represents a percentage. The test can also be used to diagnose diabetes.[1]

Hemoglobin is a protein only found in red blood cells. In fact, hemoglobin is what gives blood its bright red coloring. Since red blood cells live about an average of three months, the A1c test will reflect those red blood cells that are present in the bloodstream at the time of the test; this is why the A1c serves as an average of blood sugar control.

The main job of hemoglobin is to carry oxygen from the lungs to all the cells of the body. Hemoglobin becomes glycated or coated with glucose from the bloodstream. The amount of glucose that is present in the blood will attach to the hemoglobin protein, and increased glucose levels will reflect on the surface of the hemoglobin protein, thereby rendering a higher A1c level.[2]

Etiology and Epidemiology

The Diabetes Control and Complications Trial (DCCT)[3] was a landmark trial that provided a wealth of data on A1c and its correlation to blood glucose levels, as well as establishing specific treat to target A1c goals. From the completion of the trial, the National Glycohemoglobin Standardization Program (NGSP) was formed to define a standardized assay that was usable across laboratories.  

The DCCT trial reported that a higher mean A1c level was the dominant predictor of diabetic retinopathy progression. Tighter control shown by levels of HbA1c in the 7% range or lower, were correlated with 35-76% decrease in microvascular complications, like retinopathy, nephropathy and neuropathy, in patients with type 1 diabetes. In addition to the determination of A1c levels predicting progression of microvascular complications, the extension of DCCT into EDIC study showed benefit in the cardiovascular risk and mortality in the longterm for those patients with lower levels of HbA1c.[4][5][6]

Pathophysiology

People with diabetes need to have their A1c checked regularly to determine if their average blood glucose levels are within the target range. The American Diabetes Association (ADA) recommends that the HbA1c is checked twice a year in patients that are stable and well controlled, versus every 3 months in patients with changes in their medications, or not well controlled. [7]

Specimen Requirements and Procedure

The HbA1c test can either be done as a point of care (POC), STAT test, or by sending a sample to a laboratory. The POC test uses a STAT analyzer that evaluates the A1c from a capillary fingerstick. The laboratory test uses a teaspoon of blood drawn from a venous sample into a K2 EDTA (lavender top) tube. The sample gets processed as whole blood.

Diagnostic Tests

The venous sample A1c test may be used as a diagnostic tool in clinical practice when determining diabetes risk or onset. Due to the variability of capillary point of care testing, any A1c done by capillary sample should be confirmed with a venous sample before rendering the diagnosis.

For an HbA1c test to classify as normal, or in the non-diabetic range, the value must be below 5.7 %. Anyone with an HbA1c value of 5.7 % to 6.4 % is considered to be prediabetic, while diabetes can be diagnosed with a HbA1c of 6.5% or higher.

Tests should be sent to a laboratory certified by the NGSP to ensure results are standardized.[8][9]

Testing Procedures

The HbA1c test done by a point of care machine in a doctor's office may be less accurate than one that is drawn from a venous sample and processed in a laboratory. Typically, the results can vary by different laboratories by as much as 0.5%.

The HbA1c test should be performed using an NGSP-approved method.

Interfering Factors

There are several conditions where the HbA1c test can produce inaccurate results. People diagnosed with sickle cell anemia, thalassemia, anemia, kidney failure, liver disease, or patients receiving blood transfusions can experience altered results due to the longevity of the red blood cell. HbA1c measurement in these patients must be interpreted with caution and should be confirmed with plasma glucose samples to diagnose diabetes.[10]

A falsely low HbA1c value can result from several conditions including high altitude, pregnancy, hemorrhage, blood transfusion, erythropoietin administration, iron supplementation, hemolytic anemia, chronic kidney failure, liver cirrhosis, alcoholism, folic acid deficiency, sickle cell anemia, and spherocytosis. Vitamin C supplementation can either increase or decrease the HbA1c level depending on the method used for its measurement.[15]

On the other end of the spectrum, a falsely high HbA1c can be due to a lack of available iron in the blood. This condition can result from iron deficiency anemia, infection-induced anemia, or tumor-induced anemia. Hemoglobinopathies such as thalassemia can also cause a falsely high HbA1c. Other causes of falsely high HbA1c levels include hypertriglyceridemia, organ transplantation, and hyperglycation in certain ethnic groups. Medications such as immunosuppressants and protease inhibitors can sometimes lead to a falsely high HbA1c.[10][7][11][12]

Results, Reporting, Critical Findings

Relationship Between A1c and Glucose Level

The HbA1c percentage equates to an average glucose level in the body that the patient experienced over the past 90 days.[13][14][15]

A1c (%)       Average Blood Glucose (mg/dL)

6                  126

8                  183

10                240

12                298

14                355

Clinical Significance

Hemoglobin A1c serves as an indicator of overall glycemic control and a reflection of the average blood sugar over the past three months.[2]

Quality control and Lab Safety

Laboratories can use several methods to determine HbA1c. High performance liquid chromatography (HPLC) method is one of the most popular methods because it can eliminate labile components that other methods such as immunoassay or affinity chromatography use.[16]

The point of care (POC) machine is widely used as well to determine HbA1c levels. The variety of POC machines on the market can make it difficult to determine the one best suited for one's practice. Also, there is a shortage of information comparing the different machines. When using POC testing, one should keep in mind that POC values are often below results reported by a laboratory test, with the mean difference being -0.5%.

Enhancing Healthcare Team Outcomes

All clinicians who look after diabetic patients need to know what HbA1c means. In general, HbA1c provides a measure of the average glucose concentration over three months.

Hemoglobin A1c is often used as an outcome measure to determine if an intervention in a population is successful by showing a decrease in HbA1c by a certain percentage. There is a movement within the medical community to move away from using HbA1c as an exclusive standard of care test to measure patient response to treatment. The Estimated Average Glucose (eAG) is the newest proposed method. This method uses data obtained by continuous glucose monitors (CGMs) that record blood glucose 24 hours a day. This method gives providers a more accurate view of the blood sugar average and fluctuations, but the method is not available to all patients on a wide-spread basis.

As per ADA guidelines, the levels of HA1c should be measured twice a year in stable patients and at least four times in patients who have glucose fluctuations or those who have had a change in their diabetic treatment. Hemoglobin A1c is one of the preferred diabetes diagnostic tests today. The blood draw can occur at any time, and there are no special handling requirements. However, to ensure that the A1c value is correct, clinicians need to be aware of the causes of false-positive and false-negative results.

Since many patients with diabetes have their condition managed in outpatient clinics, the diabetic nurse should be fully aware of HbA1c values and when to refer the patient to an endocrinologist for further workup and treatment. Pharmacists are also required to fully understand and interpret this test, as they will be involved in glycemic management medication agent selection, dosing, and monitoring.  Both the nurse and/or pharmacist need to inform the treating physician regarding any changes in hemoglobin A1c and verify patient medication compliance. Hemoglobin A1c is a very valuable tool in the fight against diabetes and other glycemic control disorders, but to be effective, it functions best in an interprofessional healthcare team environment. [Level V]


Article Details

Article Author

Emily Eyth

Article Editor:

Roopa Naik

Updated:

4/5/2021 7:52:02 AM

PubMed Link:

Hemoglobin A1C

References

[1]

Gilstrap LG,Chernew ME,Nguyen CA,Alam S,Bai B,McWilliams JM,Landon BE,Landrum MB, Association Between Clinical Practice Group Adherence to Quality Measures and Adverse Outcomes Among Adult Patients With Diabetes. JAMA network open. 2019 Aug 2     [PubMed PMID: 31411713]

[2]

Sherwani SI,Khan HA,Ekhzaimy A,Masood A,Sakharkar MK, Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker insights. 2016     [PubMed PMID: 27398023]

[3]

Diabetes Control and Complications Trial Research Group.,Nathan DM,Genuth S,Lachin J,Cleary P,Crofford O,Davis M,Rand L,Siebert C, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England journal of medicine. 1993 Sep 30     [PubMed PMID: 8366922]

[4]

Nathan DM, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes care. 2014     [PubMed PMID: 24356592]

[5]

Nathan DM, Realising the long-term promise of insulin therapy: the DCCT/EDIC study. Diabetologia. 2021 May     [PubMed PMID: 33550441]

[6]

Lachin JM,Orchard TJ,Nathan DM,DCCT/EDIC Research Group., Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes care. 2014     [PubMed PMID: 24356596]

[8]

6. Glycemic Targets: {i}Standards of Medical Care in Diabetes-2019{/i}. Diabetes care. 2019 Jan     [PubMed PMID: 30559232]

[9]

Qaseem A,Wilt TJ,Kansagara D,Horwitch C,Barry MJ,Forciea MA, Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Annals of internal medicine. 2018 Apr 17     [PubMed PMID: 29507945]

[10]

Heinemann L,Freckmann G, Quality of HbA1c Measurement in the Practice: The German Perspective. Journal of diabetes science and technology. 2015 May     [PubMed PMID: 25691655]

[12]

Properties of calf endothelial cells in culture., Macarak EJ,Howard BV,Kefalides NA,, Laboratory investigation; a journal of technical methods and pathology, 1977 Jan     [PubMed PMID: 26630892]

[13]

Adenyl cyclase-cyclic AMP response during bowel obstruction., Jones CA,McArdle H,Chiu CJ,, The Journal of surgical research, 1976 Nov     [PubMed PMID: 19808928]

[14]

Cyclic nucleotides, thioldisulfide status of proteins, and cellular control processes., Rebhun LI,Miller M,Schnaitman TC,Nath J,Mellon M,, Journal of supramolecular structure, 1976     [PubMed PMID: 30049928]

[15]

Distribution pattern of radioactive labelled lipiodol-UF following intralymphatic application for therapy., Weissleder H,Pfannenstiel P,Peters PE,, Lymphology, 1976 Sep     [PubMed PMID: 19291914]

[16]

Kawano K, Quality control, quality assessment of laboratory tests, HbA1c. The Southeast Asian journal of tropical medicine and public health. 1999     [PubMed PMID: 10926271]